Showing 1-10 of 16 results for "".
- Frank Watanabe, CEOhttps://practicaldermatology.com/profiles/frank-watanabe-ceo/j1Ndlv/
- Arcutis, Huadong Announce Strategic Collab and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asiahttps://practicaldermatology.com/news/arcutis-huadong-announce-strategic-collab-and-licensing-agreement-for-topical-roflumilast-in-greater-china-and-southeast-asia/2461921/Arcutis Biotherapeutics, Inc. and Hangzhou Zhongmei Huadong Pharmaceutical Co. have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Greater China and Southeast Asia. Huadong will be responsible for de…
- Arcutis’ ZORYVE Now in Preferred Position on National Formularies for CVS Caremarkhttps://practicaldermatology.com/news/arcutis-zoryve-now-in-preferred-position-on-national-formularies-for-cvs-caremark/2461868/Arcutis Biotherapeutics, Inc.’s ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on national formularies for CVS Caremark. ZORYVE is covered for individuals with plaque ps…
- Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study of ARQ-255https://practicaldermatology.com/news/arcutis-enrolls-first-patient-in-phase-1b-alopecia-areata-study-of-arq-255/2461458/The first subject has been enrolled in a Phase 1b study evaluating Arcutis’ ARQ-255, a topical suspension of ivarmactinib, a potent and specific janus kinase 1 (JAK1) inhibitor, for the treatment of alopecia areata. ARQ-255 has been specifically formulated with Arcutis’ proprietary 4D technology t…
- MyHealthTeam and Arcutis Biotherapeutics Launch Social Network for People Living with Seborrheic Dermatitishttps://practicaldermatology.com/news/myhealthteam-and-arcutis-biotherapeutics-launch-social-network-for-people-living-with-seborrheic-dermatitis/2461454/MyHealthTeam, creator social networks for people living with chronic health conditions, today launched MySebDermTeam, an online community for those living with seborrheic dermatitis to find the people, support, and medically-reviewed information they need to better manage their condition. Created b…
- Arcutis Submits NDA for Topical Roflumilast Cream for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-submits-npa-for-topical-roflumilast-cream-for-plaque-psoriasis/2460942/Arcutis Biotherapeutics, Inc. submitted a new drug application (NDA) to the FDA for roflumilast cream for the treatment of mild-to-severe plaque psoriasis. Roflumilast cream (ARQ-151) is a once-daily topical formulation of roflumilast, a highly potent and selective inhibitor of phosphodiesterase t…
- Arcutis Biotherapeutics Plans to Initiate Phase 3 Program for ARQ-151 for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-biotherapeutics-plans-to-initiate-phase-3-program-for-arq-151-for-plaque-psoriasis/2460196/Arcutis Biotherapeutics, Inc. plans to initiate its Phase 3 program of ARQ-151 as a potential topical treatment for plaque psoriasis following its End-of-Phase 2 meeting with the FDA. The Company anticipates initiating a Phase 3 clinical trial in the first half of 2020. Frank Watanabe, Arcutis’ Pr…
- FDA Accepts Arcutis’ sNDA for Roflumilast Cream 0.15% for Treatment of AD in Adults and Children Down to Age 6https://practicaldermatology.com/news/fda-accepts-arcutis-snda-for-roflumilast-cream-015-for-treatment-of-ad-in-adults-and-children-down-to-age-6/2462159/The U.S. Food and Drug Administration (FDA) has accepted Arcutis’ supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. Roflumilast cream is a once-daily, steroid-free, phosphodiesterase-4 (PDE4) inh…
- Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosishttps://practicaldermatology.com/news/seborrheic-dermatitis-survey-shows-burdensome-and-lengthy-path-to-diagnosis/2461396/Arcutis Biotherapeutics, Inc., shared results of a nationwide survey of adults with seborrheic dermatitis and the health care providers who treat them that highlights the long path to diagnosis and the general lack of awareness and education about the disease. The online survey was conducted by The…
- Arcutis Rolls Out New Psoriasis Public Awareness Campaignhttps://practicaldermatology.com/news/arcutis-rolls-out-new-psoriasis-public-awareness-campaign/2461321/Arcutis Biotherapeutics, Inc. is launching an educational campaign designed to raise awareness about the physical and emotional impact of plaque psoriasis and empower those living with the disease to have open, honest conversations with their healthcare providers, family, and friends. The campaig…
- Prev
- Next